Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Biogen, Cambridge, MA 02142, USA.
Cell Chem Biol. 2024 Mar 21;31(3):565-576.e4. doi: 10.1016/j.chembiol.2023.11.015. Epub 2023 Dec 19.
Chemoproteomics has made significant progress in investigating small-molecule-protein interactions. However, the proteome-wide profiling of cysteine ligandability remains challenging to adapt for high-throughput applications, primarily due to a lack of platforms capable of achieving the desired depth using low input in 96- or 384-well plates. Here, we introduce a revamped, plate-based platform which enables routine interrogation of either ∼18,000 or ∼24,000 reactive cysteines based on starting amounts of 10 or 20 μg, respectively. This represents a 5-10X reduction in input and 2-3X improved coverage. We applied the platform to screen 192 electrophiles in the native HEK293T proteome, mapping the ligandability of 38,450 reactive cysteines from 8,274 human proteins. We further applied the platform to characterize new cellular targets of established drugs, uncovering that ARS-1620, a KRAS inhibitor, binds to and inhibits an off-target adenosine kinase ADK. The platform represents a major step forward to high-throughput proteome-wide evaluation of reactive cysteines.
化学生物学在研究小分子-蛋白质相互作用方面取得了重大进展。然而,由于缺乏能够在 96 孔或 384 孔板中以低输入量实现所需深度的平台,因此对蛋白质组范围内半胱氨酸配体能力的全面分析仍然具有挑战性。在这里,我们引入了一种经过改进的基于平板的平台,该平台能够根据起始量为 10 或 20μg 分别常规检测约 18000 或约 24000 个反应性半胱氨酸。这代表输入量减少了 5-10 倍,覆盖率提高了 2-3 倍。我们将该平台应用于筛选天然 HEK293T 蛋白质组中的 192 种亲电试剂,绘制了 8274 个人类蛋白质中 38450 个反应性半胱氨酸的配体能力。我们进一步将该平台应用于表征已建立药物的新细胞靶标,发现 KRAS 抑制剂 ARS-1620 与非靶标腺苷激酶 ADK 结合并抑制其活性。该平台代表了在高通量蛋白质组范围内评估反应性半胱氨酸方面的重大进展。